Enovis (ENOV) vs 10x Genomics (TXG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
10x Genomics (TXG) has outperformed Enovis (ENOV) over the past year, gaining 588.7% versus a loss of 43.6%. Over five years, TXG leads with a -47.0% price change compared with -79.7% for ENOV. 10x Genomics is the larger company by market cap ($10.51 billion vs $1.02 billion), about 10.3 times the size.
On valuation, Enovis trades at a lower forward P/E (4.9x vs 1051.9x for 10x Genomics).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ENOV | TXG |
|---|---|---|
| Share price | $17.69 | $80.65 |
| Market cap | $1.02B | $10.51B |
| 1-day change | +1.49% | +4.36% |
| YTD return | -33.60% | +394.48% |
| 1-year return | -43.61% | +588.73% |
| 5-year return | -79.70% | -47.03% |
| Forward P/E | 4.93 | — |
| EPS (TTM) | $-19.23 | $-0.59 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $642.82M |
| Revenue growth (YoY) | — | +5.25% |
| Net income (latest FY) | — | $-43.54M |
| Gross margin | — | 69.05% |
| Operating margin | — | -9.49% |
| Net margin | — | -6.77% |
| 52-week high | $34.28 | $102.81 |
| 52-week low | $16.70 | $11.16 |
| Distance from 52-week high | -48.40% | -21.55% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +112.44% | -16.34% |
| Average volume | 1.46M | 3.29M |
| Shares outstanding | 57.67M | 120.21M |
| Employees | 7,802 | 1,178 |
| Sector | Health Care | Industrials |
| Industry | Industrial Specialties | Biotechnology: Laboratory Analytical Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- 10x Genomics is about 10.3 times larger than Enovis by market value ($10.51B vs $1.02B).
- TXG has outperformed ENOV by 632.3 percentage points over the past year.
- The two companies sit in different sectors: Enovis in Health Care and 10x Genomics in Industrials.
About Enovis
ENOV stock →Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments.
Health Care · Industrial Specialties · 7,802 employees
About 10x Genomics
TXG stock →10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific.
Industrials · Biotechnology: Laboratory Analytical Instruments · 1,178 employees
ENOV vs TXG FAQ
Which is bigger, Enovis or 10x Genomics?
10x Genomics (TXG) is larger, with a market capitalization of $10.51B compared with $1.02B for Enovis (ENOV).
Which stock has performed better over the past year, ENOV or TXG?
TXG returned +588.73% over the past 12 months, compared with -43.61% for ENOV (price return, excluding dividends). Past performance does not predict future results.
Are Enovis and 10x Genomics in the same industry?
No. Enovis is in the Health Care sector, while 10x Genomics is in Industrials.